The Medical Letter on Drugs and Therapeutics
FROM
ISSUE 1621
ISSUE 1621
April 5, 2021
Ripretinib (Qinlock) for GIST (online only)
| Subscribers: Log in to read full article. Not a subscriber? Subscribe or purchase article. |
April 5, 2021 (Issue: 1621)
The FDA has approved the oral tyrosine kinase inhibitor
ripretinib (Qinlock – Deciphera) for treatment of adults
with advanced gastrointestinal stromal tumors (GISTs)
who have previously received treatment with ≥3 kinase
inhibitors, including imatinib (Gleevec, and generics).
... more
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.
Would you like to read the rest of this article? Gain access below.
Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
- Print version published and mailed biweekly (26 issues/year)
- Unlimited online access to current and past issues (1988 - present)
- Mobile App for iOS, Android, and Kindle Fire
- FREE online per issue CME/CE
Purchase this article:
Title: Ripretinib (Qinlock) for GIST (online only)
Article code: 1621f
Electronic, downloadable article - $45
Article code: 1621f
Electronic, downloadable article - $45
Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.
Recommend to your librarian
